Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 28;36(4):442–451. doi: 10.1007/s00380-020-01714-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Comparison of changes in circulating CD34+/CD133+/CD45^low cells, serum level of high sensitivity C-reactive protein and vascular endothelial function parameters. a Compared with baseline, the number of circulating CD34+/CD133+/CD45^low cells increased significantly at 24 weeks in the clopidogrel group. However, the number of these cells did not change significantly in the prasugrel group. The number of cells at 24 weeks was compatible with the two groups. b The hsCRP level did not change at 24 weeks in both clopidogrel and prasugrel groups. c The value of flow-mediated dilation (FMD) did not change at 24 weeks in the clopidogrel and prasugrel groups. d The value of the reactive hyperemia index (RHI) measured by reactive hyperemia-peripheral arterial tonometry (RH-PAT) also did not change in the clopidogrel and prasugrel groups